← Human Trials & Peer-Reviewed Studies
MicroRNA profiling in women with migraine: effects of CGRP-targeting treatment
Plain-language guide to PMID 38755568 (2024): clinical trial study of CGRP (Calcitonin Gene-Related Peptide) in 8 women, migraine.
Key Facts
- PMID
- 38755568
- Journal
- The journal of headache and pain
- Year
- 2024
- Study type
- Clinical Trial
- Authors
- Ornello R et al. (8 authors)
- DOI
- 10.1186/s10194-024-01787-2
What This Study Did, in Plain Language
What Was Tested
This clinical trial paper looks at CGRP (Calcitonin Gene-Related Peptide) in the context of migraine.
Their study aims at evaluating the expression levels of circulating microRNAs (miRNAs) according to migraine type, before and after treatment with erenumab and based on treatment response, in order to identify miRNAs with potential role as epigenetic biomarkers.
Who Took Part
The abstract describes 8 women taking part.
The age groups tagged for this paper are adults and middle-aged adults, women only.
The study included women aged 25-50 years with EM or CM treated with erenumab according to clinical indications.
An extensive miRNAs profiling was performed by qRT-PCR in small, pooled groups of ≤ 8 women each, classified according to migraine frequency (EM and CM) and the degree of response to erenumab.
How the Study Was Run
The expression levels of selected miRNAs were also validated using single miRNA assays in each woman with EM and CM.
What Was Measured
Their study aims at evaluating the expression levels of circulating microRNAs (miRNAs) according to migraine type, before and after treatment with erenumab and based on treatment response, in order to identify miRNAs with potential role as epigenetic biomarkers.
PubMed files the paper under topics including Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide, Calcitonin Gene-Related Peptide Receptor Antagonists, Gene Expression Profiling, MicroRNAs and Migraine Disorders.
The authors tagged it with the keywords Biomarkers, Epigenetics, Erenumab, Migraine prevention and Monoclonal antibodies.
What This Means in Plain Language
This is a clinical trial of CGRP (Calcitonin Gene-Related Peptide) in 8 women in people with migraine.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2024 (The journal of headache and pain), a journal based in England.
More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.
Our Notes on the Compound
CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.